- Pharmaceutical giant Novo Nordisk announced substantial reductions in the list prices of its popular GLP-1 medications, Wegovy and Ozempic, with Wegovy seeing a 50% cut and Ozempic a 35% reduction.
- According to CBS News, these new prices, set at $675 per month for each drug, will take effect starting January 1, 2027.
- This strategic move aims to improve patient access and affordability, particularly for millions in the United States living with obesity and type 2 diabetes.
- The company stated that this action directly responds to calls from private and public payers, as well as patients, to lower cost barriers, as reported by Fierce Pharma.
- The price decrease is primarily intended to benefit individuals whose out-of-pocket costs are linked to the list price, such as those with high-deductible health plans or co-insurance arrangements.
- As noted in a PR Newswire release, these changes in list price will not impact direct-to-patient, self-pay prices for the medications.
Novo Nordisk Cuts GLP-1 Drug Prices
Summarized by Catamist’s AI from other outlets’ reporting and checked for neutrality. Original sources are linked below.
Pharmaceutical giant Novo Nordisk announced significant price reductions for its popular GLP-1 medications, Wegovy and Ozempic, slashing their list prices by 50% and 35% respectively. Effective January 1, 2027, both drugs will cost $675 per month, a strategic move aimed at improving patient access and affordability, particularly for those with high-deductible health plans.
Reporting Sources
6
How this was made: Catamist’s AI summarized this story from reporting by other outlets and checked it for neutral, plain-language framing. It is a news summary, not original reporting — the original sources are linked above.
Report an issue with this article
Please sign in to report issues with this article.
Live discussion about this article
Comments
Comments are disabled for this article.
